Regeneron Operating Cycle from 2010 to 2026
| REGN Stock | USD 803.17 19.52 2.49% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 702.24440807 | Current Value 737.36 | Quarterly Volatility 233.89704266 |
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 570.9 M, Interest Expense of 24.8 M or Total Revenue of 15.1 B, as well as many indicators such as Price To Sales Ratio of 5.35, Dividend Yield of 0.0037 or PTB Ratio of 5.05. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
Regeneron | Operating Cycle | Build AI portfolio with Regeneron Stock |
Evaluating Regeneron Pharmaceuticals's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Regeneron Pharmaceuticals's fundamental strength.
Latest Regeneron Pharmaceuticals' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Regeneron Pharmaceuticals over the last few years. It is Regeneron Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regeneron Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Regeneron Operating Cycle Regression Statistics
| Arithmetic Mean | 503.85 | |
| Geometric Mean | 400.73 | |
| Coefficient Of Variation | 46.42 | |
| Mean Deviation | 202.36 | |
| Median | 577.34 | |
| Standard Deviation | 233.90 | |
| Sample Variance | 54,708 | |
| Range | 829 | |
| R-Value | 0.82 | |
| Mean Square Error | 19,077 | |
| R-Squared | 0.67 | |
| Significance | 0.000055 | |
| Slope | 38.00 | |
| Total Sum of Squares | 875,325 |
Regeneron Operating Cycle History
About Regeneron Pharmaceuticals Financial Statements
Regeneron Pharmaceuticals investors utilize fundamental indicators, such as Operating Cycle, to predict how Regeneron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 702.24 | 737.36 |
Pair Trading with Regeneron Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Regeneron Stock
| 0.62 | DRMA | Dermata Therapeutics | PairCorr |
| 0.61 | VANI | Vivani Medical | PairCorr |
| 0.57 | RAC | Race Oncology Earnings Call Next Week | PairCorr |
| 0.5 | OSE | OSE Pharma SA | PairCorr |
| 0.46 | ABNX | Abionyx Pharma SA | PairCorr |
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Regeneron diversify its offerings? Factors like these will boost the valuation of Regeneron Pharmaceuticals. Anticipated expansion of Regeneron directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regeneron Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.03) | Dividend Share 3.52 | Earnings Share 41.44 | Revenue Per Share | Quarterly Revenue Growth 0.025 |
Investors evaluate Regeneron Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regeneron Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regeneron Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Regeneron Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regeneron Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regeneron Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.